Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Current Liabilities (2016 - 2025)

Celldex Therapeutics has reported Total Current Liabilities over the past 16 years, most recently at $51.0 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $51.0 million for Q4 2025, up 29.09% from a year ago — trailing twelve months through Dec 2025 was $51.0 million (up 29.09% YoY), and the annual figure for FY2025 was $51.0 million, up 29.09%.
  • Total Current Liabilities for Q4 2025 was $51.0 million at Celldex Therapeutics, up from $46.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CLDX hit a ceiling of $51.0 million in Q4 2025 and a floor of $14.2 million in Q3 2021.
  • Median Total Current Liabilities over the past 5 years was $27.0 million (2024), compared with a mean of $26.0 million.
  • Biggest five-year swings in Total Current Liabilities: surged 106.72% in 2022 and later plummeted 47.76% in 2023.
  • Celldex Therapeutics' Total Current Liabilities stood at $16.5 million in 2021, then rose by 12.6% to $18.6 million in 2022, then skyrocketed by 67.25% to $31.1 million in 2023, then rose by 26.91% to $39.5 million in 2024, then rose by 29.09% to $51.0 million in 2025.
  • The last three reported values for Total Current Liabilities were $51.0 million (Q4 2025), $46.5 million (Q3 2025), and $33.0 million (Q2 2025) per Business Quant data.